Iovance Biotherapeutics IOVA 深 沪
已收盘 02-06 16:00:00 美东时间
2.53
+0.170
+7.20%
华盛通- 最 高2.58
- 今 开2.42
- 成交量 691.35万股
- 最 低 2.42
- 昨 收 2.36
- 总市值 10.04亿
- 52周最高 6.09
- 市盈率 静 --
- 换手率 1.74%
- 52周最低 1.6385
- 委 比 87.38%
- 总股本 3.97亿
- 历史最高 54.208
- 量 比 0.59
- 振 幅 6.78%
- 历史最低 1.6385
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Iovance Biotherapeutics Reports Best-in-Class Real-World Response Rates for Amtagvi in Advanced Melanoma
Iovance Biotherapeutics Reports Best-in-Class Real-World Response Rates for Amtagvi in Advanced Melanoma Iovance Biotherapeutics Inc. announced new real-world clinical data for Amtagvi® (lifileucel), a one-time T cell therapy for advanced melanoma. The data, presented at the 2026 Tandem Meetings of
02-06 06:15
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
<p>Announcing impressive real-world data for Amtagvi® (lifileucel) demonstrating a best-in-class profile in advanced melanoma treatment. With a 44% objective response rate (ORR) and 73% disease control rate in 41 patients, the therapy shows higher efficacy when administered earlier in treatment lines. Amtagvi, the first one-time T cell therapy for solid tumors, also exhibits unprecedented five-year durability and survival rates, highlighting its ...
02-05 22:15
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics granted 17 new employees stock options for 97,710 shares, exercisable at $2.22, vesting over three years. The options were awarded under the amended 2021 Inducement Plan, aligning with Nasdaq rules. Iovance focuses on innovative TIL therapies for cancer treatment.
01-16 22:15
Iovance Highlights Amtagvi Momentum and Confirms 2025 Guidance
Iovance Biotherapeutics ( ($IOVA) ) just unveiled an announcement. On January 9...
01-09 20:58
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics granted stock options covering 43,150 shares to four new, non-executive employees on December 18, 2025. The options were granted under the Amended and Restated 2021 Inducement Plan and have an exercise price of $2.46, the closing price of the Company’s common stock on the grant date. Each stock option vests over a three-year period, with one-third vesting on the first anniversary of the employee’s start date and the remain...
2025-12-19 22:15
美股牛股 | Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%
Medline上市首日大涨超41%，最新市值超322亿美元，为今年最大IPO；Udemy涨超12%，与Coursera合并以扩大全球AI教育市场份额>>
2025-12-18 19:07
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $10
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $9 to $10.
2025-12-18 01:45
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $9
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $4 to $9.
2025-11-24 22:30
